Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ) News

Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ): $129.70

2.56 (-1.94%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

B

Add JAZZ to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#2 of 359

in industry

Filter JAZZ News Items

JAZZ News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

JAZZ News Highlights

  • For JAZZ, its 30 day story count is now at 8.
  • Over the past 14 days, the trend for JAZZ's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about JAZZ are HR, TOP and AIM.

Latest JAZZ News From Around the Web

Below are the latest news stories about JAZZ PHARMACEUTICALS PLC that investors may wish to consider to help them evaluate JAZZ as an investment opportunity.

7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World

With the Federal Reserve previously engaged in a bitter – and seemingly, at times desperate – struggle against blisteringly hot inflation, the narrative for growth stocks to buy now frankly didn’t resonate very well with many investors.

Josh Enomoto on InvestorPlace | December 29, 2023

Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals

After a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug.

Yahoo | December 22, 2023

Jazz Pharmaceuticals' Post-Traumatic Stress Disorder Drug Disappoints In Mid-Stage Study

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced top-line results from the Phase 2 trial of JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy and safety in adults with post-traumatic stress disorder (PTSD). The trial did not meet the primary endpoint. There was not a statistically significant decrease in PTSD symptom severity as measured by the Clinician-Administered PTSD Scale between JZP150 (4mg or 0.3mg) compared to placebo from base

Yahoo | December 22, 2023

Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2 trial (NCT05178316) evaluating JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy and safety in adults with post-traumatic stress disorder (PTSD). The trial did not meet the primary endpoint. There was not a statistically significant decrease in total PTSD symptom severity as measured by the Clinician Administered PTSD Scale (CAPS-5) between JZP150 (

Yahoo | December 21, 2023

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update on Monday, January 8, 2024, at 2:15 p.m. PST / 10:15 p.m. GMT.

Yahoo | December 20, 2023

3 No-Brainer Stocks to Buy With $500 Right Now

You don't need a mountain of cash to build wealth on Wall Street.

Yahoo | December 20, 2023

Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Yahoo | December 8, 2023

Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 8, 2023

Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Serving our Global Communities

NORTHAMPTON, MA / ACCESSWIRE / December 8, 2023 / Jazz PharmaceuticalsOriginally Published in Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact ReportManagement ApproachWe aim to be an engaged corporate citizen globally and in ...

Yahoo | December 8, 2023

Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nine company-sponsored presentations, including five late-breaking abstracts, will be shared at the 2023 American Epilepsy Society (AES) annual meeting, being held December 1-5 in Orlando, Florida.

Yahoo | December 1, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!